Home  |  SUPARTZ Patient  |  Appropriate Patients

Appropriate Patients

Ideal candidates for SUPARTZ are patients with knee OA (1) who:

• Have not responded to conservative non-pharmacologic therapy, including physical therapy
• Have not responded to simple analgesics such as acetaminophen

Dosing

25 mg/2.5 mL active ingredient per syringe(1)

Directions for use

SUPARTZ is administered by intra-articular injections once a week (1 week apart) for a total of 5 injections. Some patients may experience benefit with 3 injections given at weekly intervals. This has been noted in a study in which patients treated with 3 injections were followed for 90 days. (1, 2) Injection of subcutaneous lidocaine or similar local anesthetic may be recommended prior to injection of SUPARTZ.

Recommendations for managing knee OA pain

Contraindications to SUPARTZ include (1)

• Previous allergic reactions to sodium hylaluronate products, including SUPARTZ
• Infections or skin diseases in the area where the injection will be given
• Allergies to products from birds, such as feathers, eggs, and poultry

The safety and effectiveness of SUPARTZ have not been established in pregnant women, lactating women, or children.

Patient Testimonial

Watch a short video about a patient who suffered from knee osteoarthritis and benefited from SUPARTZ, right from the first series of injections.

SUPARTZ is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

You should not use SUPARTZ if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found here or by contacting customer service at 800-396-4325.